Advertisement

Relative Contribution of Incretins to the Glucose Lowering Effect of DP IV Inhibitors in Type 2 Diabetes Mellitus (T2DM)

  • Simon A. Hinke
  • Raymond A. Pederson
  • Christopher H. S. McIntosh
Part of the Advances in Experimental Medicine and Biology book series (volume 575)

5. Conclusions

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Keywords

Insulin Release Gastric Inhibitory Polypeptide Dipeptidyl Peptidase Improve Glucose Tolerance Incretin Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahrén B, Holst JJ, Martensson H, Balkan B, 2000, Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol. 404: 239–245.CrossRefPubMedGoogle Scholar
  2. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A, 2004, Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 27: 2874–2880.PubMedGoogle Scholar
  3. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A, 2004, Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 89: 2078–2084.CrossRefPubMedGoogle Scholar
  4. Ahrén B, Hughes TE, 2005, Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. 146: 2055–2059.CrossRefPubMedGoogle Scholar
  5. Baggio L, Kieffer TJ, Drucker DJ, 2000, Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology. 141: 3703–3709.CrossRefPubMedGoogle Scholar
  6. Cheeseman CI, Tsang R, 1996, The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am J Physiol. 271: G477–482.PubMedGoogle Scholar
  7. Creutzfeldt W, Ebert R, 1985, New developments in the incretin concept. Diabetologia. 28: 565–573.CrossRefPubMedGoogle Scholar
  8. Deacon CF, Johnsen AH, Holst JJ, 1995, Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 80: 952–957.CrossRefPubMedGoogle Scholar
  9. Deacon CF, Hughes TE, Holst JJ, 1998, Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 47: 764–769.PubMedGoogle Scholar
  10. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ, 2000, Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 85: 3575–3581.CrossRefPubMedGoogle Scholar
  11. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ, 2001, Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes. 50: 1588–1597.PubMedGoogle Scholar
  12. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ, 2002, Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol. 172: 355–362.CrossRefPubMedGoogle Scholar
  13. Del Prato S, 2003, Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia. 46Suppl 1: M2–8.PubMedGoogle Scholar
  14. Demuth H-U, 1990, Recent developments in inhibiting cysteine and serine proteases. J Enzyme Inhib. 3: 249–278.PubMedGoogle Scholar
  15. Ebert R, Creutzfeldt W, 1982, Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinology. 111: 1601–1606.PubMedCrossRefGoogle Scholar
  16. Ebert R, Unger H, Creutzfeldt W, 1983, Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia. 24: 449–454.CrossRefPubMedGoogle Scholar
  17. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK, 1994, The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects. Regul Pept. 51: 63–74.CrossRefPubMedGoogle Scholar
  18. Foltz M, Meyer A, Theis S, Demuth H-U, Daniel H, 2004, A rapid in vitro screening for delivery of peptide-derived peptidase inhibitors as potential drug candidates via epithelial peptide transporters. J Pharmacol Exp Ther. 310: 695–702.CrossRefPubMedGoogle Scholar
  19. Gault VA, O’Harte FPM, Harriott P, Mooney MH, Green BD, Flatt PR, 2003, Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP-and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. 46: 222–230.PubMedGoogle Scholar
  20. Gault VA, Flatt PR, O’Harte FPM, 2003, Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun. 308: 207–213.CrossRefPubMedGoogle Scholar
  21. Gelling RW, Coy DH, Pederson RA, Wheeler MB, Hinke S, Kwan T, McIntosh CHS, 1997, GIP(6–30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1–42 action in vitro. Regul Pept. 69: 151–154.CrossRefPubMedGoogle Scholar
  22. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B, 1993, Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 268: 19650–19655.PubMedGoogle Scholar
  23. Green BD, Gault VA, O’Harte FPM, Flatt PR, 2004, Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des. 10: 3651–3662.CrossRefPubMedGoogle Scholar
  24. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ, 2004, Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes. 53: 1326–1335.PubMedGoogle Scholar
  25. Hinke SA, Pospisilik JA, Demuth H-U, Manhart S, Kühn-Wache K, Hoffmann T, Nishimura E, Pederson RA, McIntosh CHS, 2000, Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagons degradation products and DPIV-resistant analogs. J Biol Chem. 275: 3827–3834.CrossRefPubMedGoogle Scholar
  26. Hinke SA, Manhart S, Pamir N, Demuth H-U, RW G, Pederson RA, McIntosh CHS, 2001, Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim Biophys Acta. 1547: 143–155.PubMedGoogle Scholar
  27. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CHS, Demuth H-U, 2002a, Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun. 291: 1302–1308.CrossRefPubMedGoogle Scholar
  28. Hinke SA, McIntosh CHS, Hoffmann T, Kühn-Wache K, Wagner L, Bar J, Manhart S, Wermann M, Pederson RA, Demuth H-U, 2002b, On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors. Diabetes Care. 25: 1490–1491; author reply 1491–1492.PubMedGoogle Scholar
  29. Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth H-U, McIntosh CHS, 2002, Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 51: 652–661.PubMedGoogle Scholar
  30. Hinke SA, Lynn F, Ehses J, Pamir N, Manhart S, Kühn-Wache K, Rosche F, Demuth H-U, Pederson RA, McIntosh CHS, 2003, Glucose-dependent insulinotropic polypeptide (GIP): development of DP IV-resistant analogues with therapeutic potential. Adv Exp Med Biol. 524: 293–301.PubMedGoogle Scholar
  31. Hinke SA, Gelling R, Manhart S, Lynn F, Pederson RA, Kühn-Wache K, Rosche F, Demuth H-U, Coy D, McIntosh CHS, 2003, Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP). Biol Chem. 384: 403–407.CrossRefPubMedGoogle Scholar
  32. Hinke SA, Manhart S, Kühn-Wache K, Nian C, Demuth H-U, Pederson RA, McIntosh CHS, 2004, [Ser2]-and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo. J Biol Chem. 279: 3998–4006.CrossRefPubMedGoogle Scholar
  33. Hinke SA, Hellemans K, Schuit FC, 2004, Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal. J Physiol. 558: 369–380.CrossRefPubMedGoogle Scholar
  34. Hinke SA, Manhart S, Speck M, Pederson RA, Demuth H-U, McIntosh CHS, 2004a, In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide. Life Sci. 75: 1857–1870.PubMedGoogle Scholar
  35. Hoffmann T, Glund K, McIntosh C, Pederson R, Hanefeld M, Rosenkranz B, Demuth H-U, 2001, DPPIV inhibitor treatment of type II diabetes. Ed: S. Mitzutani. Cell-surface aminopeptidases: basic and clinical aspects. 381–387.Google Scholar
  36. Holst JJ, Ørskov C, 2001, Incretin hormones-an update. Scand J Clin Lab Invest Suppl. 234: 75–85.CrossRefPubMedGoogle Scholar
  37. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, Zimmermann B, Voigt K, 1995, Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 58: 149–156.CrossRefPubMedGoogle Scholar
  38. Joy SV, Rodgers PT, Scates AC, 2005, Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother. 39: 110–118.PubMedGoogle Scholar
  39. Kahn SE, Porte D, Jr., 1988, Islet dysfunction in non-insulin-dependent diabetes mellitus. Am J Med. 85: 4–8.CrossRefPubMedGoogle Scholar
  40. Kieffer TJ, McIntosh CHS, Pederson RA, 1995, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 136: 3585–3596.CrossRefPubMedGoogle Scholar
  41. Kieffer TJ, 2004, Gastro-intestinal hormones GIP and GLP-1. Ann Endocrinol (Paris). 65: 13–21.Google Scholar
  42. Kindmark H, Pigon J, Efendic S, 2001, Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. J Clin Endocrinol Metab. 86: 2015–2019.CrossRefPubMedGoogle Scholar
  43. Knudsen LB, Pridal L, 1996, Glucagon-like peptide-1-(9–36) amide is a major metabolite of glucagon-like peptide-1-(7–36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol. 318: 429–435.CrossRefPubMedGoogle Scholar
  44. Kreymann B, Williams G, Ghatei MA, Bloom SR, 1987, Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet. 2: 1300–1304.CrossRefPubMedGoogle Scholar
  45. Kühn-Wache K, Manhart S, Hoffmann T, Hinke SA, Gelling R, Pederson RA, McIntosh CHS, Demuth H-U, 2000, Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance. Adv Exp Med Biol. 477: 187–195.PubMedGoogle Scholar
  46. Larsen J, Hylleberg B, Ng K, Damsbo P, 2001, Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care. 24: 1416–1421.PubMedGoogle Scholar
  47. Lewis JT, Dayanandan B, Habener JF, Kieffer TJ, 2000, Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology. 141: 3710–3716.CrossRefPubMedGoogle Scholar
  48. Lund PK, Goodman RH, Habener JF, 1981, Intestinal glucagon mRNA identified by hybridization to a cloned islet cDNA encoding a precursor. Biochem Biophys Res Commun. 100: 1659–1666.CrossRefPubMedGoogle Scholar
  49. Lynn FC, Pamir N, Ng EH, McIntosh CHS, Kieffer TJ, Pederson RA, 2001, Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 50: 1004–1011.PubMedGoogle Scholar
  50. Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N, McIntosh CHS, Pederson RA, 2003, A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. Faseb J. 17: 91–93.PubMedGoogle Scholar
  51. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N, 2000, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A. 97: 6874–6879.CrossRefPubMedGoogle Scholar
  52. Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, Drucker DJ, 2003, International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 55: 167–194.CrossRefPubMedGoogle Scholar
  53. McIntosh CHS, Demuth H-U, Pospisilik JA, Pederson R, 2005, Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 128: 159–165.CrossRefPubMedGoogle Scholar
  54. Meier JJ, Gallwitz B, Nauck MA, 2003, Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs. 17: 93–102.CrossRefPubMedGoogle Scholar
  55. Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, Gallwitz B, Nauck MA, 2004, Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab. 286: E621–625.CrossRefPubMedGoogle Scholar
  56. Meier JJ, Gallwitz B, Kask B, Deacon CF, Holst JJ, Schmidt WE, Nauck MA, 2004, Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes. 53Suppl 3: S220–224.PubMedGoogle Scholar
  57. Meneilly GS, Bryer-Ash M, Elahi D, 1993, The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care. 16: 110–114.PubMedGoogle Scholar
  58. Mentlein R, Gallwitz B, Schmidt WE, 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 214: 829–835.CrossRefPubMedGoogle Scholar
  59. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y, 1999, Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA. 96: 14843–14847.CrossRefPubMedGoogle Scholar
  60. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y, 2002, Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 8: 738–742.CrossRefPubMedGoogle Scholar
  61. Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J, 1997, High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem. 272: 21201–21206.CrossRefPubMedGoogle Scholar
  62. Nauck M, Stockmann F, Ebert R, Creutzfeldt W, 1986, Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 29: 46–52.CrossRefPubMedGoogle Scholar
  63. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W, 1993, Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 91: 301–307.PubMedGoogle Scholar
  64. Nauck MA, El-Ouaghlidi A, 2005, The therapeutic actions of DPP-IV are not mediated by glucagon-like peptide-1. Diabetologia. In PressGoogle Scholar
  65. Nielsen LL, Baron AD, 2003, Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 4: 401–405.PubMedGoogle Scholar
  66. O’Harte FPM, Gray AM, Flatt PR, 1998, Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J Endocrinol. 156: 237–243.CrossRefPubMedGoogle Scholar
  67. O’Harte FPM, Abdel-Wahab YH, Conlon JM, Flatt PR, 1998a, Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochim Biophys Acta. 1425: 319–327.PubMedGoogle Scholar
  68. O’Harte FPM, Mooney MH, Flatt PR, 1999, NH2-terminally modified gastric inhibitory polypeptide exhibits aminopeptidase resistance and enhanced antihyperglycemic activity. Diabetes. 48: 758–765.PubMedGoogle Scholar
  69. O’Harte FPM, Mooney MH, Kelly CM, Flatt PR, 2000, Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J Endocrinol. 165: 639–648.CrossRefPubMedGoogle Scholar
  70. Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, Miyawaki K, Yamada Y, Seino Y, McIntosh CHS, Pederson RA, 2003, Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am J Physiol Endocrinol Metab. 284: E931–939.PubMedGoogle Scholar
  71. Pauly RP, Rosche F, Wermann M, McIntosh CHS, Pederson RA, Demuth H-U, 1996, Investigation of glucose-dependent insulinotropic polypeptide-(1–42) and glucagon-like peptide-1-(7–36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem. 271: 23222–23229.CrossRefPubMedGoogle Scholar
  72. Pauly RP, Demuth H-U, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CHS, Pederson RA, 1999, Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism. 48: 385–389.CrossRefPubMedGoogle Scholar
  73. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS, Demuth H-U, 1998, Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 47: 1253–1258.PubMedGoogle Scholar
  74. Pederson RA, Satkunarajah M, McIntosh CHS, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, Wheeler MB, 1998, Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor-/-mice. Diabetes. 47: 1046–1052.PubMedGoogle Scholar
  75. Perley MJ, Kipnis DM, 1967, Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest. 46: 1954–1962.PubMedCrossRefGoogle Scholar
  76. Pospisilik JA, Hinke SA, Pederson RA, Hoffmann T, Rosche F, Schlenzig D, Glund K, Heiser U, McIntosh CHS, Demuth H-U, 2001, Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul Pept. 96: 133–141.CrossRefPubMedGoogle Scholar
  77. Pospisilik JA, Stafford SG, Demuth H-U, McIntosh CHS, Pederson RA, 2002, Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemichyperinsulinemic clamp study. Diabetes. 51: 2677–2683.PubMedGoogle Scholar
  78. Pospisilik JA, Stafford SG, Demuth H-U, Brownsey R, Parkhouse W, Finegood DT, McIntosh CHS, Pederson RA, 2002a, Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 51: 943–950.PubMedGoogle Scholar
  79. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth H-U, McIntosh CHS, Pederson RA, 2003, Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 52: 741–750.PubMedGoogle Scholar
  80. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A, Hansotia T, Drucker DJ, Wollheim C, Burcelin R, Thorens B, 2004, Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest. 113: 635–645.CrossRefPubMedGoogle Scholar
  81. Raufman JP, Singh L, Singh G, Eng J, 1992, Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem. 267: 21432–21437.PubMedGoogle Scholar
  82. Ritzel R, Ørskov C, Holst JJ, Nauck MA, 1995, Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia. 38: 720–725.PubMedGoogle Scholar
  83. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ, 1996, Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 2: 1254–1258.CrossRefPubMedGoogle Scholar
  84. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C, 1993, Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor. Diabetes. 42: 1678–1682.PubMedGoogle Scholar
  85. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR, 1997, Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest. 27: 533–536.CrossRefPubMedGoogle Scholar
  86. Tseng C-C, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM, 1996, Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest. 98: 2440–2445.PubMedGoogle Scholar
  87. Tseng C-C, Zhang XY, Wolfe MM, 1999, Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol. 276: E1049–1054.PubMedGoogle Scholar
  88. Unger RH, Eisentraut AM, 1969, Entero-insular axis. Arch Intern Med. 123: 261–266.CrossRefPubMedGoogle Scholar
  89. Vilsbøll T, Krarup T, Madsbad S, Holst JJ, 2002, Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 45: 1111–1119.CrossRefPubMedGoogle Scholar
  90. Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ, 2003, The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab. 88: 4897–4903.CrossRefPubMedGoogle Scholar
  91. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR, 1995, Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest. 95:417–421.PubMedCrossRefGoogle Scholar
  92. Weir GC, Mojsov S, Hendrick GK, Habener JF, 1989, Glucagonlike peptide I (7–37) actions on endocrine pancreas. Diabetes. 38: 338–342.PubMedGoogle Scholar
  93. Wolf R, Rosche F, Hoffmann T, Demuth H-U, 2001, Immunoprecipitation and liquid chromatographic-mass spectrometric determination of the peptide glucose-dependent insulinotropic polypeptides GIP1-42 and GIP3-42 from human plasma samples. New sensitive method to analyze physiological concentrations of peptide hormones. J Chromatogr A. 926: 21–27.CrossRefPubMedGoogle Scholar
  94. Wolf R, Hoffmann T, Rosche F, Demuth H-U, 2004, Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 803: 91–99.PubMedGoogle Scholar
  95. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I, 2002, Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun. 298: 779–784.CrossRefPubMedGoogle Scholar
  96. Zander M, Christiansen A, Madsbad S, Holst JJ, 2004, Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care. 27: 1910–1914.PubMedGoogle Scholar
  97. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ, 2001, Additive glucose-lowering effects of glucagonlike peptide-1 and metformin in type 2 diabetes. Diabetes Care. 24:720–725.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Simon A. Hinke
    • 1
  • Raymond A. Pederson
    • 2
  • Christopher H. S. McIntosh
    • 2
  1. 1.Department of Metabolism and Endocrinology, Diabetes Research CenterVrije Universiteit BrusselBrusselsBelgium
  2. 2.Department of Cellular and Physiological SciencesUniversity of British ColumbiaVancouverCanada

Personalised recommendations